title: International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).
abstract: In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.
authors.affiliation: Lymphoma Service.
authors.forename: A
authors.initials: A
authors.lastname: Younes
authors.affiliation: Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA.
authors.forename: P
authors.initials: P
authors.lastname: Hilden
authors.affiliation: Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France.
authors.forename: B
authors.initials: B
authors.lastname: Coiffier
authors.affiliation: Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
authors.forename: A
authors.initials: A
authors.lastname: Hagenbeek
authors.affiliation: Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France.
authors.forename: G
authors.initials: G
authors.lastname: Salles
authors.affiliation: Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, USA.
authors.forename: W
authors.initials: W
authors.lastname: Wilson
authors.affiliation: Peter MacCallum Cancer Centre and University of Melbourne, Australia.
authors.forename: J F
authors.initials: JF
authors.lastname: Seymour
authors.affiliation: Pediatrics Department, Roswell-Park Cancer Institute, Buffalo, USA.
authors.forename: K
authors.initials: K
authors.lastname: Kelly
authors.affiliation: Department of Haemato-Oncology, Barts Cancer Institute, London, UK.
authors.forename: J
authors.initials: J
authors.lastname: Gribben
authors.affiliation: Department of Internal Medicine, Universität des Saarlandes, Homburg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Pfreunschuh
authors.affiliation: Department of Hematology, Université de Lille 2, Lille, France.
authors.forename: F
authors.initials: F
authors.lastname: Morschhauser
authors.affiliation: Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York.
authors.forename: H
authors.initials: H
authors.lastname: Schoder
authors.affiliation: Lymphoma Service.
authors.forename: A D
authors.initials: AD
authors.lastname: Zelenetz
authors.affiliation: Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York.
authors.forename: J
authors.initials: J
authors.lastname: Rademaker
authors.affiliation: Department of Oncology, Stanford University, Stanford.
authors.forename: R
authors.initials: R
authors.lastname: Advani
authors.affiliation: Genentech, San Francisco, USA.
authors.forename: N
authors.initials: N
authors.lastname: Valente
authors.affiliation: Statistics, EORTC, Brussels, Belgium.
authors.forename: C
authors.initials: C
authors.lastname: Fortpied
authors.affiliation: Mayo Clinic, Rochester, USA.
authors.forename: T E
authors.initials: TE
authors.lastname: Witzig
authors.affiliation: British Columbia Cancer Agency, Vancouver, Canada.
authors.forename: L H
authors.initials: LH
authors.lastname: Sehn
authors.affiliation: Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Engert
authors.affiliation: Fox Chase Cancer Center, Philadelphia, USA.
authors.forename: R I
authors.initials: RI
authors.lastname: Fisher
authors.affiliation: Department of Hematology, University of Bologna, Bologna.
authors.forename: P-L
authors.initials: PL
authors.lastname: Zinzani
authors.affiliation: Department of Diagnostic Medicine, University of Modena, Modena, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Federico
authors.affiliation: Department of Hematology, University of Copenhagen, Denmark.
authors.forename: M
authors.initials: M
authors.lastname: Hutchings
authors.affiliation: Children's National Health System, Washington, USA.
authors.forename: C
authors.initials: C
authors.lastname: Bollard
authors.affiliation: Lymphoma and Stem Cell Transplantation Program, Charles University, Prague, Czech Republic.
authors.forename: M
authors.initials: M
authors.lastname: Trneny
authors.affiliation: Janssen Research & Development, Spring House, USA.
authors.forename: Y A
authors.initials: YA
authors.lastname: Elsayed
authors.affiliation: Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Tobinai
authors.affiliation: Massachusetts General Hospital, Center for Lymphoma, Boston.
authors.forename: J S
authors.initials: JS
authors.lastname: Abramson
authors.affiliation: U.T. M.D.Anderson Cancer Center, Houston.
authors.forename: N
authors.initials: N
authors.lastname: Fowler
authors.affiliation: John Theurer Cancer Center, Hackensack University Medical Center, Hackensack.
authors.forename: A
authors.initials: A
authors.lastname: Goy
authors.affiliation: Cleveland Clinic, Cleveland, USA.
authors.forename: M
authors.initials: M
authors.lastname: Smith
authors.affiliation: Mayo Clinic, Rochester, USA.
authors.forename: S
authors.initials: S
authors.lastname: Ansell
authors.affiliation: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.
authors.forename: J
authors.initials: J
authors.lastname: Kuruvilla
authors.affiliation: Medicine Clinic III, Ludwig Maximilian University, Munich, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Dreyling
authors.affiliation: Haemato-Oncology, Hôpital Saint Louis, Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Thieblemont
authors.affiliation: Divisions of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, USA.
authors.forename: R F
authors.initials: RF
authors.lastname: Little
authors.affiliation: Department of Hematology, University Hospital Centre Zagreb, Zagreb, Croatia.
authors.forename: I
authors.initials: I
authors.lastname: Aurer
authors.affiliation: Academic Medical Center, Amsterdam, The Netherlands.
authors.forename: M H J
authors.initials: MHJ
authors.lastname: Van Oers
authors.affiliation: Celgene, Summit.
authors.forename: K
authors.initials: K
authors.lastname: Takeshita
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, USA.
authors.forename: A
authors.initials: A
authors.lastname: Gopal
authors.affiliation: Haematology Department, Plymouth University, UK.
authors.forename: S
authors.initials: S
authors.lastname: Rule
authors.affiliation: Oncology, UCLA, Los Angeles, USA.
authors.forename: S
authors.initials: S
authors.lastname: de Vos
authors.affiliation: Servier, Neuilly sur Seine, France.
authors.forename: I
authors.initials: I
authors.lastname: Kloos
authors.affiliation: University of Michigan Comprehensive Cancer Center, Ann Arbor, USA.
authors.forename: M S
authors.initials: MS
authors.lastname: Kaminski
authors.affiliation: Nuclear Medicine, Hôpitaux Universitaires Henri Mondor, Créteil, France.
authors.forename: M
authors.initials: M
authors.lastname: Meignan
authors.affiliation: Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York.
authors.forename: L H
authors.initials: LH
authors.lastname: Schwartz
authors.affiliation: Weill Cornell Medicine and and New York Presbyterian Hospital, New York.
authors.forename: J P
authors.initials: JP
authors.lastname: Leonard
authors.affiliation: University of Pennsylvania School of Medicine, Philadelphia, USA.
authors.forename: S J
authors.initials: SJ
authors.lastname: Schuster
authors.affiliation: Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA.
authors.forename: V E
authors.initials: VE
authors.lastname: Seshan
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D032921:Consensus; D003287:Contrast Media / Q000008:administration & dosage; D018450:Disease Progression; D018572:Disease-Free Survival; D023381:Endpoint Determination; D019788:Fluorodeoxyglucose F18 / Q000008:administration & dosage; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000592:standards*; D011237:Predictive Value of Tests; D066066:Response Evaluation Criteria in Solid Tumors; D013997:Time Factors; D014057:Tomography, X-Ray Computed / Q000592:standards*; D016896:Treatment Outcome; D047368:Tumor Burden
chemical_list: D000970:Antineoplastic Agents; D003287:Contrast Media; D019788:Fluorodeoxyglucose F18
keywords: FDG-PET; immunotherapy; lymphoma; response criteria; targeted therapy; waterfall plots